Coagulation factor IX gene locus (F9 locus)

The Coagulation factor IX gene locus (F9) is the specific region of genomic DNA located at Xq27.1 that encodes the Factor IX protein, an essential component of the intrinsic pathway of blood coagulation (NCBI Gene ID: 2158). Mutations in this locus result in Hemophilia B, a condition where patients suffer from prolonged bleeding due to the inability to form stable blood clots (National Library of Medicine, Hemophilia B). This genomic site is a target for advanced genetic therapies, including gene addition and gene editing, which seek to provide a long-term cure by restoring the production of functional Factor IX (FDA, HEMGENIX). While many current gene therapies utilize adeno-associated virus (AAV) vectors to deliver episomal DNA, newer strategies focus on site-specific integration or direct repair of the F9 locus using tools like CRISPR/Cas9 or Zinc Finger Nucleases (ZFNs) (Sangamo Therapeutics, SB-FIX). These corrective integration approaches aim to achieve stable, lifelong expression of the protein by inserting a functional transgene into the endogenous locus or a designated safe harbor (Nature Communications, Site-specific integration of Factor IX). Safety considerations for targeting this site include the risk of off-target mutations, insertional mutagenesis, and potential immune reactions against the delivery vehicle or the newly synthesized protein (NEJM, Gene Therapy for Hemophilia B). Monitoring efficacy typically involves measuring circulating Factor IX activity levels and assessing clinical bleeding phenotypes (FDA, BEQVEZ).

Other names

Factor IX geneF9 geneFIX locusHemophilia B gene locusXq27.1 locus

Restoration of Factor IX protein production through the delivery of a functional F9 transgene or the site-specific integration of genetic material into the host genome to correct the underlying genetic deficiency (FDA, HEMGENIX; Sangamo Therapeutics, SB-FIX).